DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisLinda M. Henricks, Jan H.M. Schellens, Geert Frederix et al.|The Lancet Oncology|2018Cited by 419
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trialMartine E.D. Chamuleau, Marie José Kersten, Coreline N. Burggraaff et al.|Haematologica|2019Cited by 53